For those that didn't notice, there were some minor changes to the catalysts slide during Leslie's presentation at the Emergence conference versus what we saw in the EGM presentation in January. Those changes are highlighted below, but the major 3 being:
1) azer-cel Phase 1B updates moves forward from 2H 2025 into 1H 2025. 2) The reference to Orphan Drug Designation is also dropped, leaving only Fast Track Designation (for reference, Vaxinia recevied FTD before it received ODD).
3) Phase 2 startup for Vaxinia has also changed, so likely 2026?
I did email about the 2nd indication for Vaxinia being NMIBC being opened per the slide, but to-date no response. I will plug in a chaser on that.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)